Intracellular action of an exogenous low-molecular-weight synthetic protease inhibitor, E3123, in cerulein-induced acute pancreatitis in rats

1994 ◽  
Vol 15 (2) ◽  
pp. 119-127
Author(s):  
Naohiro Sata ◽  
Yutaka Atomi ◽  
Wataru Kimura ◽  
Akira Kuroda ◽  
Tetsuichiro Muto ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Acute Pancreatitis ◽  
Protease Inhibitor ◽  
Low Molecular Weight ◽  
Intracellular Action

A New Synthetic Protease Inhibitor, E-3123, Prevents Lysosomal and Mitochondrial Fragility in Rat Caerulein-Induced Pancreatitis

1992 ◽  
Vol 20 (3) ◽  
pp. 211-217
Author(s):  
T Hirano ◽  
T Manabe
Keyword(s):  
Molecular Weight ◽  
Acute Pancreatitis ◽  
Protease Inhibitor ◽  
Protective Effect ◽  
Malate Dehydrogenase ◽  
Cathepsin B ◽  
Exocrine Pancreas ◽  
Low Molecular Weight

The study investigated the protective effect of a new synthetic protease inhibitor, E-3123, a 4-guanidinobenzoate methanesulphonate, on the exocrine pancreas in caerulein-induced pancreatitis of rats both in vivo and in vitro. Hyperamylasaemia, pancreatic oedema and congestion of amylase, as well as cathepsin B leakage from lysosomes and malate dehydrogenase leakage from mitochondria, were prevented by infusion of 5 mg/kg.h E-3123 particularly when infused for 2 h before and during 5 μg/kg.h caerulein infusion for 3.5 h. The results indicate that E-3123 plays its protective roles against pancreatitis in the subcellular compartments such as lysosomes and mitochondria, and that such a low molecular weight protease inhibitor as E-3123 may be clinically useful in the treatment of acute pancreatitis.

scholarly journals Localisation of a low-molecular-weight bronchial protease inhibitor in the peripheral human lung.

Thorax ◽  
1983 ◽  
Vol 38 (3) ◽  
pp. 180-183 ◽  
Author(s):  
H W Mooren ◽  
J A Kramps ◽  
C Franken ◽  
C J Meijer ◽  
J A Dijkman
Keyword(s):  
Molecular Weight ◽  
Protease Inhibitor ◽  
Human Lung ◽  
Low Molecular Weight

Preventive Management of Hypertriglyceridemia in Pregnancy: A Case Report

2020 ◽  
pp. 73-77
Author(s):  
Mei Peng ◽  
Jian Huang ◽  
Yiling Ding
Keyword(s):  
Molecular Weight ◽  
Acute Pancreatitis ◽  
Low Molecular Weight Heparin ◽  
Single Case ◽  
Pregnancy Termination ◽  
Low Molecular Weight ◽  
Treatment Management ◽  
Entire Pregnancy ◽  
Threatening Condition ◽  
In Pregnancy

Background: Hypertriglyceridemia in pregnancy is a rare but well-known cause of hypertriglyceridemia-induced acute pancreatitis (HTGP) in pregnancy, a life-threatening condition that lacks an established guideline for treatment management. Case presentation: We report a case with a successful treatment management of hypertriglyceridemia in pregnancy. A pregnant woman had been with hypertriglyceridemia for more than seven years and a history of pregnancy termination due to the development of HTGP. Eleven months after her last pregnancy termination, the woman was pregnant again and she started managing her elevated levels of lipids in the second trimester throughout the pregnancy, with low molecular weight heparin and then combined with metformin, to prevent thrombosis. Results: The entire pregnancy progressed smoothly, and the triglycerides' level fluctuated during the second and the third trimester of pregnancy with a range of 16.15 to 47.65 mmol/L. A full-term delivery, with a reasonable outcome for both mother and newborn, was obtained. Compared with her last pregnancy, the outcomes of recent pregnancy were better off. Conclusion: Low molecular weight heparin combined with metformin can avoid maternal hypertriglyceridemia-induced pancreatitis in this single case. To our knowledge, such a combination of treatment management of patients with hypertriglyceridemia in pregnancy to prevent acute pancreatitis has not been reported previously.

Sign in / Sign up

Export Citation Format

Share Document